Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 153

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 153
---
     | Share Based     
 Compensation(1) |   |
|:----------------------------------------------------------------------------------------------------|:----|:-------------------------------------|--------:|:----|:-----------------------------------------------|:--|:----|:----------------|:--|
| All directors and senior management as a group, consisting of five persons as of December 31, 2024. |     | $                                    | 218,000 |     | $                                              | - |     | $               | - |

For
so long as we qualify as a foreign private issuer, we will not be required to comply with the proxy rules applicable to U.S. domestic
companies regarding disclosure of the compensation of certain executive officers on an individual basis. Pursuant to the Companies Law,
we will be required, after we become a public company, to disclose the annual compensation of our five most highly compensated officers
on an individual basis. This disclosure will not be as extensive as that required of a U.S. domestic issuer. We intend to commence providing
such disclosure, at the latest, in the annual proxy statement for our first annual meeting of shareholders following the closing of this
offering, which will be filed under cover of a report on Form 6-K.

As
of December 31, 2024, options to purchase 15,000 Ordinary Shares granted to one of our directors were outstanding under our Option Plan
at an exercise price of $9.933 per share. The following table sets forth information regarding options granted to our executive officers
and directors during the year ended December 31, 2024:

| Name                |     | Grant Date     |     | Stock   
 Options |        |     | Exercise 
 Price    |       |     | Expiration     
 Date           |
|:--------------------|:----|:---------------|:----|:--------|-------:|:----|:---------|------:|:----|:---------------|
| Mr. Keith Valentine |     | September 2015 |     |         | 15,000 |     | $        | 9.933 |     | September 2025 |

As
approved by our board of directors, subject to and following the completion of this offering, we intend to grant options to purchase up
to 16,071 Ordinary Shares and up to 194,098 Ordinary Shares to Mr. Pini Ben Elazar and Dr. Ehud Geller, respectively. The options will
have an exercise price of NIS 0.01 and will expire on the ten-year-ann